SURVIVAL OUTCOMES AMONG PATIENTS WITH HIGH-GRADE GLIOMA: A SINGLE INSTITUTION RETROSPECTIVE STUDY

Abstract

BackgroundThe prognosis for glioma patients is poor, despite recent advances in diagnosis and treatment. Understanding Glioma’s clinical characteristics and predictive factors is crucial for patient treatment and management. ObjectivesTo assess the survival duration of HGG patients at a single facility and to discover clinical determinants of treatment outcome in HGG treated with a combined modality approach in Zhianawa Cancer Center. Patients and MethodsThis study included 133 patients with high-grade gliomas diagnosed between January 2015 and January 2020; these patients were referred to the Zhianawa Cancer Center. A retrospective analysis of the clinical data included survival outcomes, tumour characteristics, and demographic information. While the Cox regression model was used for the evaluation of multivariate data to look at the risk factors for mortality, on the other hand, survival data were analyzed using Kaplan-Meier curves with a log-rank test. ResultsIn this particular patient cohort, grade IV glioma (83.9%), grade III glioma  (16.1), and glioblastoma  (81.4%) were the most common pathological types. A poor prognosis was associated with not using temozolomide, having a Karnofsky Performance Score (KPS) of less than 70%, and not receiving radiotherapy. Univariate analysis showed low KPS (70) to increase the risk of mortality. Patients who had radiotherapy with normal fractionation, concurrent chemotherapy, and radiotherapy adjuvant chemotherapy had the highest overall survival rates. ConclusionMortality was significantly related to aging, absence of seizures, presence of motor alteration, pathological grade IV gliosarcoma, glioblastoma multiform, and non-standard radiation dose.